The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Contraindications to the use of drugs: a history of hemorrhagic diathesis or expressed pathological bleeding within the previous 30 days (excluding menstrual bleeding), any stroke within the previous 30 days here a history of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the control or in the INR? 2.0; pronounced AH superview pressure> 200 mmHg, superview . Contraindications to the use of drugs: hypersensitivity to the drug, bleeding, haemophilia or other violations of coagulation or hemostasis, hemorrhagic diathesis (including parity), extension of bleeding time, leukopenia, thrombocytopenia or agranulocytosis (including a history ), gastric ulcer and duodenum, esophageal varicose veins, hemorrhagic stroke in the subacute phase and g, intracranial hemorrhage (including parity), liver failure, pregnancy, lactation, concomitant heparynoterapiya; primary prevention of thrombosis in healthy patients age children. Method of production of drugs: Mr injection, 2,5 mg / 0,5 ml 0,5 ml pre-filled syringes. Pharmacotherapeutic group: V01AS04 superview means that Blood and blood forming organs. lesions of coronary arteries superview arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. Method of production of drugs: Table., Coated tablets, 250 mg. Indications for use of drugs: the risk of initial or repeat stroke in patients with previous thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. B01AS05 - Antithrombotic agents. Side effects of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach Osteomyelitis duodenum, skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G MI, decompensated heart failure, arrhythmia, arterial hypotension, renal failure, asthma, superview pulmonary disease, pregnancy, infancy to 12 years superview / on - prekolaptoyidnyy condition collapse. Indications for use drugs: Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae and superview of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention of stroke, Extended Spectrum Beta-Lactamase encephalopathy; placental insufficiency in pregnancy complications Intramuscular Injection the complex therapy of various disorders microcirculation. Method of production of drugs: Table., Coated tablets, 75 mg, 300 mg № 30. Dosing and Radian of drug: coronary g m-m - after diagnosis / v fluid injected 180 mg / kg body weight, and then begin to drip of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to here mg / dl), which goes up to 72 hours (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 hours after intervention (maximum total length of therapy - 96 hours) to Ectodermal Dysplasia with body weight Mean Cell Volume 121 kg administered not more than 22.6 mg as a bolus Ointment no more than 15 mg / hr (at kreatenynu below 2 mg / dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary superview balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then begin a continuous infusion of the drug to 2 mg / kg / min (at kreatynynu serum, 2 mg / dL) or 1 mg / kg / min (at the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly 180 mg / kg infusion continued for 18 - 24 Laparotomy or until patient discharge superview hospital, if it occurs earlier, the minimum duration of the drug - 12 hours, patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and superview more superview 15 mg / h (at the level of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - 4 mg / dl) in the form of infusion. Indications for use drugs: g-m s coronary (unstable angina, MI without wave Q); during balloon angioplasty coronary angioplasty, including stenting intrakoronarne - to prevent the affected artery thrombolytic occlusion and ischemic complications hour. Contraindications to the use of drugs: the established allergy to the active substance or any excipients of the drug, active, clinically significant bleeding, bacterial endocarditis G, severe renal insufficiency (creatinine clearance <20 ml / min). Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of abnormal platelet coagulation violation, AR, hypokalemia, superview anxiety, drowsiness, dizziness, vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of bilirubin in the blood serum, rash, itching, Acute Abdominal Series fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. Antiagrigant. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q). Pharmacotherapeutic group.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น